(S)-2-methyl-3-quinoxalin-6-yl-propionaldehyde | 362611-71-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: (S)-2-methyl-3-quinoxalin-6-yl-propionaldehyde
• 英文别名: (2S)-2-methyl-3-quinoxalin-6-ylpropanal
• CAS: 362611-71-0
• 化学式: C₁₂H₁₂N₂O
• 分子量: 200.24
• InChiKey: NFPMGIHGKCNKNA-VIFPVBQESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  42.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (S)-2-methyl-3-quinoxalin-6-yl-propionaldehyde 、 ((4S,4as,8ar)-去氢异喹啉-4-基)(4-(3,4-二氟苯基)哌嗪-1-基)甲酮 在 三乙酰氧基硼氢化钠 作用下， 以 1,2-二氯乙烷 为溶剂， 生成 [4-(3,4-Difluoro-phenyl)-piperazin-1-yl]-[(4S,4aS,8aR)-2-(2(S)-methyl-3-quinoxalin-6-yl-propyl)-decahydro-isoquinolin-4-yl]-methanone
  参考文献：
  名称：

  Decahydroisoquinoline derivatives as novel non-peptidic, potent and subtype-selective somatostatin sst3 receptor antagonists

  摘要：

  Starting from non-peptidic sst(1)-selective somatostatin receptor antagonists, first compounds with mixed sst(1)/sst(3) affinity were identified by directed structural modifications. Systematic optimization of these initial leads afforded novel, enantiomerically pure, highly potent and sst(3)-subtype selective somatostatin antagonists based on a (4S,4aS,8aR)-decahydroisoquinoline-4-carboxylic acid core moiety. These compounds can efficiently be synthesized and show promising PK properties in rodents. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.01.063
• 作为产物：
  描述：

  (S)-2-methyl-3-quinoxalin-6-yl-propan-1-ol 在 戴斯-马丁氧化剂 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 (S)-2-methyl-3-quinoxalin-6-yl-propionaldehyde
  参考文献：
  名称：

  Decahydroisoquinoline derivatives as novel non-peptidic, potent and subtype-selective somatostatin sst3 receptor antagonists

  摘要：

  Starting from non-peptidic sst(1)-selective somatostatin receptor antagonists, first compounds with mixed sst(1)/sst(3) affinity were identified by directed structural modifications. Systematic optimization of these initial leads afforded novel, enantiomerically pure, highly potent and sst(3)-subtype selective somatostatin antagonists based on a (4S,4aS,8aR)-decahydroisoquinoline-4-carboxylic acid core moiety. These compounds can efficiently be synthesized and show promising PK properties in rodents. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.01.063

文献信息

• Decahydro-isoquinolines
  申请人：——

  公开号：US20030120072A1

  公开（公告）日：2003-06-26

  1 The invention provides compounds of formula (I), wherein A, B and R are as defined in the description, and the preparation thereof. The compounds of formula (I) are useful as somatostatin receptor antagonists.

  该发明提供了式（I）的化合物，其中A、B和R如描述中所定义，并其制备方法。式（I）的化合物可用作生长抑素受体拮抗剂。
• [EN] DECAHYDRO-ISOQUINOLINES<br/>[FR] DÉCAHYDRO-ISOQUINOLINES
  申请人：NOVARTIS AG

  公开号：WO2001070731A1

  公开（公告）日：2001-09-27

  The invention provides compounds of formula (I), wherein A, B and R are as defined in the description, and the preparation thereof. The compounds of formula (I) are useful as somatostatin receptor antagonists.

  本发明提供了式（I）的化合物，其中A、B和R如描述中所定义，并提供其制备方法。式（I）的化合物可用作生长抑素受体拮抗剂。
• DECAHYDRO-ISOQUINOLINES
  申请人：Novartis AG

  公开号：EP1268466B1

  公开（公告）日：2005-06-22
• US6635647B2
  申请人：——

  公开号：US6635647B2

  公开（公告）日：2003-10-21
• Decahydroisoquinoline derivatives as novel non-peptidic, potent and subtype-selective somatostatin sst3 receptor antagonists
  作者：Thomas Troxler、Konstanze Hurth、Karl-Heinrich Schuh、Philippe Schoeffter、Daniel Langenegger、Albert Enz、Daniel Hoyer

  DOI：10.1016/j.bmcl.2010.01.063

  日期：2010.3

  Starting from non-peptidic sst(1)-selective somatostatin receptor antagonists, first compounds with mixed sst(1)/sst(3) affinity were identified by directed structural modifications. Systematic optimization of these initial leads afforded novel, enantiomerically pure, highly potent and sst(3)-subtype selective somatostatin antagonists based on a (4S,4aS,8aR)-decahydroisoquinoline-4-carboxylic acid core moiety. These compounds can efficiently be synthesized and show promising PK properties in rodents. (C) 2010 Elsevier Ltd. All rights reserved.